Subcutaneous · GLP-1 agonist
Liraglutide
518 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
518
Ongoing
46
Recruiting
26
Completed
367
Sites
3,600
Countries
67
Endpoints
8,104
Composite endpoints
478
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Early Phase 1
5
Phase 1
64
Phase 1/2
8
Phase 2
64
Phase 2/3
6
Phase 3
106
Phase 4
133
Not applicable
132
Trials by status
Not yet recruiting
5
By invitation
3
Recruiting
26
Active, not recruiting
12
Completed
367
Terminated
20
Withdrawn
17
Suspended
1
Unknown
67
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
2,045
Safety / tolerability / PK
1,710
Cardiometabolic biomarkers
1,222
Weight & body composition
1,139
Other (unclassified)
617
Other clinical outcomes
597
Patient-reported / QoL
361
Renal / kidney
114
MASH / liver
105
Cardiovascular outcomes
101
Heart failure
93
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
366
Body weight, absolute change (kg)Weight
323
Fasting glucose, changeGlycemic
277
Postprandial glucoseGlycemic
252
Documented hypoglycemiaSafety/PK
244
HbA1c <7.0% achievementGlycemic
189
Treatment-emergent AEs (any)Safety/PK
180
Heart rate, changeBiomarker
133
Waist circumference, changeWeight
128
Body weight, % changeWeight
122
HbA1c <6.5% achievementGlycemic
109
AUC₀-∞Safety/PK
106
Systolic BP, changeBiomarker
97
Triglycerides, changeBiomarker
92
BMI, changeWeight
91
HOMA-IR (insulin sensitivity)Glycemic
87
Immunogenicity (ADA)Safety/PK
86
Total cholesterol, changeBiomarker
85
LDL-C, changeBiomarker
78
HDL-C, changeBiomarker
76
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
518 of 518
Showing 1-25 of 518 trials